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A correlation of mobilisation regimens and outcome during autologous haematopoietic stem  
cell mobilisation and transplantation
SYT Chan, CO Tsui, J Chan, AKW Lie, AYH Leung
Department of Medicine, Queen Mary Hospital, Hong Kong
introduction: Autologous haematopoietic stem cell transplantation (ASCT) is the mainstay of treatment for plasma 
cell myeloma and selected cases of lymphoma. Haematopoietic stem cell (HSC) can be mobilised using combination 
of chemotherapy and granulocyte-colony stimulating factor (G-CSF). However it is associated with treatment toxicity 
and the need for prolonged hospitalisation. HSC can also be mobilised using G-CSF alone, but the yield may be 
lower. Plerixafor, a CXC chemokine receptor 4 (CXCR-4) antagonist, was recently approved by the US FDA in patients 
who failed G-CSF HSC mobilisation. In the present study, we compared the HSC yield and engraftment after ASCT in 
patients who underwent HSC mobilisation with these regimens.
Methods: Consecutive patients who underwent ASCT for plasma cell myeloma between 2009 and 2010 were 
retrospectively analysed. Total CD34+ cells collected, number of apheresis sessions and haematopoietic recovery after 
ASCT was correlated with their HSC mobilisation regimens. Numerical data were compared using Mann-Whitney U 
test and categorical data was evaluated using χ2 test. A P value of less than 0.05 was considered statistically significant. 
Results: A total of 28 patients were analysed; 18 patients have received cyclophosphamide (3 g/m2) and G-CSF for 
mobilisation (Cy+G-CSF), 10 received G-CSF of whom five required plerixafor (G-CSF+P) to achieve target cell dose of 
2x106/kg body weight. Patients receiving Cy+G-CSF required longer duration of hospitalisation when compared with 
G-CSF±Mozobil group. Most patients in the Cy+G-CSF group (n=15) required only one harvest whereas all patients in 
the G-CSF required more than one (P<0.01). There was no significant difference in neutrophil engraftment as well as 
hospital stay during ASCT in these patients.
Conclusion: The use of plerixafor improves the stem cell yield when added to G-CSF as mobilisation, and has a 
significant less hospital stay when compared with cyclophosphamide as mobilisation. 
Acknowledgement: Plerixafor was supplied by the compassionate program of Genzyme Asia Ltd.
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The electrophysiological hallmark of cells and tissues isolated from failing hearts is prolongation of action potential 
duration (APD), resulted from down-regulation of repolarising K+ currents and/or alterations in depolarising Na+ and 
Ca2+ currents, which predisposes the failing heart to lethal ventricular tachyarrhythmia (ventricular tachycardia [VT] 
and ventricular fibrillation [VF]). C11, a small synthetic Cl– channel, exhibits membrane-repolarising power. Therefore, 
we hypothesise C11 corrects the delayed repolarisation and shortens APD at cellular level, thus modifying ventricular 
arrhythmogenic substrate at whole heart level. First, we demonstrated APD reduction upon C11 application (30 μM) 
at 37ºC to isolated guinea pig ventricular cardiomoyocytes with patch-clamp experiments in whole cell configuration 
(Figure:	upper	panel). 
To examine whether C11 works in disease model, pig hearts with chronic myocardial infarction (MI) were optically 
mapped. Electrocardiograms (ECGs) [Figure:	middle	panel] and the optical mapping signals with optical timing maps 
(Figure:	lower	panel) displayed the attenuation of VF to VT in the presence of C11 (30 μM).
In conclusion, C11 alleviated VF in our ex-vivo pig heart model with chronic MI. Further investigation in the ionic 
properties of C11 will be worthy to further dissect the underlying mechanism of function posing potential use of C11 
in clinical prospect.
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